Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: Press Release On New Patents

Press Release On New Patents 16 Nov 2016 10:19 #8040

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1280
  • Thank you received: 18
Press release on new patents issued at 11:15 am ET!:yep: :nice:

Please Log in or Create an account to join the conversation.

Press Release On New Patents 16 Nov 2016 10:36 #8041

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110

rodney.strongg wrote: Press release on new patents issued at 11:15 am ET!:yep: :nice:


The text of the release:

Nov 16, 2016
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the “Company”) announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has over 90 global patents issued and another 55 patent applications pending around the globe. Several of Cytori’s recently-issued patents contain claims providing protections for Cytori’s program in the use of Cytori Cell Therapy™ for treating scleroderma. Cytori recently completed enrollment in its STAR approval trial in the US for this indication.
On November 1, 2016, US Patent No. 9480718 was issued. This patent contains claims applying to the use of adipose derived cells to treat peripheral vascular diseases (“PVD”), which are blood circulation disorders that affect the blood carrying vessels of the body that can narrow, experience spasm or become blocked. PVD is often a contributory process in scleroderma. This patent has term at least through 2022 and claims the use of Cytori Cell Therapy™ for PVD, including but not limited to PVD associated with scleroderma.
On November 8, 2016, US Patent No. 9486484 was issued. This patent provides protections around the use of adipose-derived cells for the treatment of edema. Edema, also known as ‘swelling’, is often accompanied by increased blood flow and is a very common secondary clinical manifestation of numerous inflammatory and immune-related conditions. Specifically, edema contributes directly to the diminished hand dysfunction found often in the acute phases of scleroderma. The ‘484 patent term lasts through at least 2029.
Other recently issued patents strengthen Cytori’s osteoarthritis program. Last month, US Patent No. 9463203 was issued. The ‘203 patent protects the use of adipose-derived cells for treating cartilage defects, including but not limited to osteoarthritic defects, defects in the articular cartilage and defects in meniscus. Earlier this year, Cytori completed the ACT-OA clinical trial, a phase IIb trial assessing the use of adipose-derived cells for the treatment of osteoarthritis of the knee. The ‘203 patent term lasts through at least 2022.
The European Patent Office also recently issued European Patent No. EP2617427 to Cytori. The ‘427 Patent protects the use of adipose-derived cells for restoring tears in cartilage such as those present in osteoarthritic joints, and has a patent term at least through 2024.
On November 15, 2016 US Patent No. 9492483 was issued. The ‘483 Patent relates to the use of adipose-derived regenerative cells for the treatment of burn, and area in which Cytori has had an active research program for several years in conjunction with the US Government. The ‘483 patent term lasts at least through December 2022.
“Cytori has amassed a large global intellectual property position and continues to expand and strengthen the portfolio through internal R&D efforts and targeted in-licensing,” noted John D. Harris, Vice President and General Manager, Cell Therapy. “The recent patents specifically serve to support our current development efforts in scleroderma, osteoarthritis, and burn.”

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Press Release On New Patents 16 Nov 2016 12:11 #8042

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2768
  • Thank you received: 199
Are we supposed to regard OA and Burn patents only having 5 years left as good news ?
Wait to the cardiac patents expire and you will see the treatment come to life (for other companies that is)

Niche player.

Please Log in or Create an account to join the conversation.

Press Release On New Patents 16 Nov 2016 12:23 #8043

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1280
  • Thank you received: 18
Hedgefund, the release says "at least" until 2022.

Please Log in or Create an account to join the conversation.

Press Release On New Patents 16 Nov 2016 12:45 #8044

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2768
  • Thank you received: 199
LOL, I can read.
Terms of extension are specific and can be quite limiting at times. Of course a few can play the game very well. Cytori does nothing well ! OK, loose money !!!
Best to see if they even get FDA approval for marketing in the first place, otherwise the patents aren't worth too much anyway.

Please Log in or Create an account to join the conversation.

Press Release On New Patents 16 Nov 2016 15:07 #8046

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1280
  • Thank you received: 18
It is a good question as to why only 2022??

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.090 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites